- Home
- GALT vs CATX Comparison
GALT vs CATX Comparison
Compare GALT & CATX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | GALT | CATX |
|---|---|---|
| Founded | 2000 | 1983 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Medical/Dental Instruments |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 261.1M | 211.1M |
| IPO Year | N/A | N/A |
Fundamental Metrics
Financial Performance| Metric | GALT | CATX |
|---|---|---|
| Price | $4.12 | $2.74 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 3 | 9 |
| Target Price | $8.50 | ★ $11.56 |
| AVG Volume (30 Days) | 813.8K | ★ 1.4M |
| Earning Date | 11-14-2025 | 11-10-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $1,075,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $1.07 | $1.60 |
| 52 Week High | $7.13 | $5.39 |
Technical Indicators
Market Signals| Indicator | GALT | CATX |
|---|---|---|
| Relative Strength Index (RSI) | 36.28 | 53.90 |
| Support Level | $3.90 | $2.67 |
| Resistance Level | $4.19 | $2.88 |
| Average True Range (ATR) | 0.54 | 0.19 |
| MACD | -0.19 | 0.02 |
| Stochastic Oscillator | 17.22 | 64.44 |
Price Performance
Historical ComparisonAbout GALT Galectin Therapeutics Inc.
Galectin Therapeutics Inc is a clinical-stage biopharmaceutical company. The company focuses on drug research and development to create new therapies for fibrotic disease, cancer, and selected other diseases. Its galectin-3 inhibitor is belapectin (GR-MD-02), which has been demonstrated in preclinical models to reverse liver fibrosis and cirrhosis.
About CATX Perspective Therapeutics Inc.
Perspective Therapeutics Inc is a radiopharmaceutical development company that is pioneering advanced treatment applications for cancers throughout the body. The Company has a proprietary technology that utilizes the alpha-emitting isotope Lead-212 (212Pb) to deliver powerful radiation specifically to cancer cells via specialized targeting moieties.